Skip to main content
Skip to main menu Skip to spotlight region Skip to secondary region Skip to UGA region Skip to Tertiary region Skip to Quaternary region Skip to unit footer


Antibody-Drug Conjugates: Recent Advances in Site-Specific Conjugation Offers Payload Diversity

Kyle Minder, speaker
Kyle Minder
Graduate Student, Department of Chemistry
University of Georgia
Chemistry Building, Room 400
Organic Seminar

Antibody-drug conjugate (ADC) development has seen recent improvement through employment of targeted conjugate synthesis strategies. Methods that optimize delivery of antibodies, linkers, and conjugated drug compounds have emerged. Through these methods, higher drug conjugation density, increased linker stability, and lower unconjugated antibody concentrations can be achieved. Dual conjugation, a process by which two different conjugated drugs can be delivered, has become attractive for increased ADC potency. In this seminar, a discreet background will be presented to familiarize the audience with these advances. Expedited conjugation through intelligent cross-linker utilization will be presented. Finally, recent strategy of dual conjugation through Formylglycine-generating enzymes, as well as orthogonal Cysteine employment, will be covered.

Illustrations for abstract: Intelligent Linker Design, Site-Specific Formylglycine Generation, and Orthogonal Cysteine Conjugation Strategies


1. Boschanski, M.;  Krüger, T.;  Karsten, L.;  Falck, G.;  Alam, S.;  Gerlach, M.;  Müller, B.;  Müller, K. M.;  Sewald, N.; Dierks, T., Site-Specific Conjugation Strategy for Dual Antibody–Drug Conjugates Using Aerobic Formylglycine-Generating Enzymes. Bioconjugate Chemistry 2021, 32 (6), 1167-1174.

2. Walker, J. A.;  Sorkin, M. R.;  Ledesma, F.;  Kabaria, S. R.;  Barfield, R. M.;  Rabuka, D.; Alabi, C. A., Hydrophilic Sequence-Defined Cross-Linkers for Antibody–Drug Conjugates. Bioconjugate Chemistry 2019, 30 (11), 2982-2988.

3. Levengood, M. R.;  Zhang, X.;  Hunter, J. H.;  Emmerton, K. K.;  Miyamoto, J. B.;  Lewis, T. S.; Senter, P. D., Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody–Drug Conjugates. Angewandte Chemie International Edition 2017, 56 (3), 733-737.

4. Agarwal, P.; Bertozzi, C. R., Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development. Bioconjugate Chemistry 2015, 26 (2), 176-192.

5. Beck, A.;  Goetsch, L.;  Dumontet, C.; Corvaïa, N., Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery 2017, 16 (5), 315-337.

Support Us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.

Got More Questions?

Undergraduate inquiries: 

Registration and credit

AP Credit, Section Changes, Overrides,

Graduate inquiries:

Contact Us!

Assistant to the Department Head: Donna Spotts, 706-542-1919 

Main office phone: 706-542-1919 

Main Email:

Head of Chemistry: Prof. Jason Locklin